[Prevention of sudden cardiac death and implantable cardioverter defibrillators: Understanding the competitive risk!]

Julien Rischard; Kumar Narayanan; Rodrigue Garcia; Eloi Marijon

doi:10.1016/j.lpm.2019.09.010

[Prevention of sudden cardiac death and implantable cardioverter defibrillators: Understanding the competitive risk!]

Presse Med. 2019 Dec;48(12):1401-1405. doi: 10.1016/j.lpm.2019.09.010. Epub 2019 Nov 4.

[Article in French]

Authors

Julien Rischard¹, Kumar Narayanan², Rodrigue Garcia³, Eloi Marijon⁴

Affiliations

¹ Hôpital Européen Georges-Pompidou, département de cardiologie, unité de rythmologie, 75015 Paris, France.
² Medicover, Cardiology Departement, Hyderabad, Inde.
³ CHU de Poitiers, unité de rythmologie, 86000, Poitiers, France.
⁴ Hôpital européen Georges-Pompidou, département de cardiologie, unité de rythmologie, 20, rue Leblanc, 75908 Paris cedex 15, France. Electronic address: [email protected].

PMID: 31699540
DOI: 10.1016/j.lpm.2019.09.010

Abstract

Sudden cardiac death represents a major public health issue, with up to 50% of the cardiovascular mortality. Coronary artery disease and dilated cardiomyopathy both represent almost 90% of sudden cardiac death burden. Primary prevention using implantable cardioverter defibrillator relies, in this population, on the left ventricle ejection fraction simple measurement. In this paper, we aim to discuss in which extent a better understanding of competing risk situation may help for a better patient selection and eventually for optimizing primary prevention using implantable cardioverter defibrillator.

Publication types

Review

MeSH terms

Cardiomyopathy, Dilated / epidemiology
Cardiomyopathy, Dilated / therapy
Death, Sudden, Cardiac / epidemiology
Death, Sudden, Cardiac / prevention & control*
Defibrillators, Implantable*
Humans
Patient Selection
Primary Prevention / instrumentation
Primary Prevention / methods
Risk
Risk Assessment
Risk Factors
Ventricular Dysfunction, Left / epidemiology
Ventricular Dysfunction, Left / therapy